Objectives Given the rapidly evolving therapeutic landscape for type 2 diabetes (T2D) and chronic kidney disease (CKD), this study aimed to characterise the clinical profiles and real-world outcomes ...
Galderma (SIX: GALD), the pure-play dermatology category leader, today released new clinical data confirming nemolizumab's rapid onset of action on itch and sleep, with significant improvements ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback